H
Hans Lilja
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 513
Citations - 39718
Hans Lilja is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Prostate cancer & Prostate-specific antigen. The author has an hindex of 93, co-authored 493 publications receiving 37236 citations. Previous affiliations of Hans Lilja include Cleveland Clinic & University of Tampere.
Papers
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin.
Hans Lilja,Anders Christensson,Ulrika Dahlén,Marja-Terttu Matikainen,O. Nilsson,Kim Pettersson,T Lövgren +6 more
TL;DR: To characterize the PSA immunoreactivity in serum, monoclonal antibodies produced against PSA and a polyclonal rabbit IgG against alpha 1-antichymotrypsin were used in the design of three noncompetitive PSA assays and an immunoreactive 25- to 40-kDa compound was the minor fraction.
Journal ArticleDOI
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Jonas Hugosson,Sigrid Carlsson,Gunnar Aus,Svante Bergdahl,Ali Khatami,Pär Lodding,Carl-Gustaf Pihl,Johan Stranne,Erik Holmberg,Hans Lilja,Hans Lilja +10 more
TL;DR: It is shown that prostate cancer mortality was reduced almost by half over 14 years, however, the risk of over-diagnosis is substantial and the number needed to treat is at least as high as in breast-cancer screening programmes.